SRI-286, a Thiosemicarbazole, in Combination with Mefloquine and Moxifloxacin for Treatment of Murine Mycobacterium avium Complex Disease

@article{Bermudez2004SRI286AT,
  title={SRI-286, a Thiosemicarbazole, in Combination with Mefloquine and Moxifloxacin for Treatment of Murine Mycobacterium avium Complex Disease},
  author={Luiz E. Bermudez and Peter Kolonoski and L E Seitz and Mary Petrofsky and Robert C. Reynolds and Martin Wu and Lowell S. Young},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2004},
  volume={48},
  pages={3556 - 3558}
}
ABSTRACT Treatment of Mycobacterium avium disease remains challenging when macrolide resistance develops. We infected C57 beige mice and treated them with mefloquine, SRI-286, and moxifloxacin. SRI-286 (80 mg/kg) was bactericidal in the liver. Mefloquine plus moxifloxacin or mefloquine plus SRI-286 were better than mefloquine alone. 
View on ASMUSA
europepmc.org
33 Citations
Background Citations
6
Results Citations
1

33 Citations

Imidazole-Thiosemicarbazide Derivatives as Potent Anti-Mycobacterium tuberculosis Compounds with Antibiofilm Activity

The antimycobacterial potential of ITDs with the ability to penetrate Mtb-infected human macrophages and significantly inhibit the intracellular growth of tubercle bacilli and suppress Mtb biofilm formation was observed.

Design, Synthesis, and SAR Studies of Mefloquine‐Based Ligands as Potential Antituberculosis Agents

The design, synthesis, and structure–activity studies of mefloquine analogues, a well-known antimalarial drug still used today in spite of its neuropsychiatric side-effects that include dizziness, headache, insomnia, and vivid dreams, are reported.

Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.

The Synergetic Effect of Sitafloxacin-Arbekacin Combination in the Mycobacteroides abscessus Complex

The synergistic effect of the sitafloxacin-arbekacin combination against M. abscessus complex, a highly resistant subspecies of M.Abscessus, was demonstrated.

Mefloquine synergism with anti-tuberculosis drugs and correlation to membrane effects: Biologic, spectroscopic and molecular dynamics simulations studies.

Quinoline: a promising antitubercular target.

Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria

This is a first report on the mechanism of action of TAC, demonstrating the CMASs as its cellular targets in mycobacteria, and the implications of this study may be important for the design of alternative strategies for tuberculosis treatment.

Novel Organic Salts Based on Mefloquine: Synthesis, Solubility, Permeability, and In Vitro Activity against Mycobacterium tuberculosis

Novel potential formulations of a repurposed drug, the antimalarial mefloquine (MFL), which was combined with organic anions as chemical adjuvants, are reported, which exhibited improved permeability and diffusion through synthetic membranes.

Synthesis, anti-mycobacterial and cytotoxic evaluation of substituted isoindoline-1,3-dione-4-aminoquinolines coupled via alkyl/amide linkers

The compound with a butyl chain as a spacer between the two pharmacophores and piperidine as the secondary amine component on the isoindoline ring was the most potent and non-cytotoxic among the synthesized compounds.

Novel quinoline and naphthalene derivatives as potent antimycobacterial agents.

References

SHOWING 1-10 OF 16 REFERENCES

Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.

A patient with chronic lymphatic leukemia who developed disseminated cutaneous MAC lesions refractory to conventional antimycrobial therapy responded to the addition of compounds that were recently discovered to have anti-MAC activity (linezolid, moxifloxacin as well as GM-CSF).

Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.

Macrolides are the core of effective drug regimens for the treatment of Mycobacterium avium complex (MAC) disease and the combination of MFQ and MXF significantly reduced, the load of CLR-R in both the liver and the spleen.

Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against Mycobacterium avium

Moxifloxacin at both concentrations in combination with ethambutol was significantly more active than each drug alone and rifabutin showed inhibitory activity only in the blood.

[Mycobacterium avium complex].

These two species are difficult to differentiate and therefore they are also referred to collectively as Mycobacterium avium-intracellulare (MAI), which is ubiquitous but only a minority of people exposed to MAC will acquire infection.

In vitro and in vivo activities of clarithromycin against Mycobacterium avium

Clarithromycin was the most effective compound in these tests and was effective in reducing the viable bacterial counts in the spleen when it was administered subcutaneously or orally at a dose of 25 mg/kg.

In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis

ABSTRACT On 10% oleic acid–albumin–dextrose–catalase-enriched 7H11 agar medium, the MIC at which 90% of the isolates are inhibited for 20 strains of Mycobacterium tuberculosis was 0.5 μg of…

Pathogenesis of nontuberculous mycobacteria infections.

Nontuberculous mycobacteria in the HIV infected patient.

Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial.

Mefloquine Is Active In Vitro and In Vivo againstMycobacterium avium Complex

A combination of mefloquine and ethambutol showed significantly more activity than did either drug alone in liver, spleen, and blood; the combination was also bactericidal againstM.